LifeVantage Q3 Revenue Plunges 25%, GLP-1 Honeymoon Over

What happened

LifeVantage reported Q3 FY2026 revenue of $43.7 million, down 25.2% year-over-year, with adjusted EBITDA halved to $3.2 million. The Americas segment fell 28.9%, while Asia/Pacific & Europe declined 7.7%. Diluted EPS dropped to $0.11 from $0.26 a year ago. This sharp reversal follows a period where the Master Report highlighted FY25 as an inflection year driven by the MindBody GLP-1 System, which contributed $40.8 million in FY25. The new data suggests that growth catalyst is fading, as total revenue decline accelerated and profitability compressed. The company's net cash position and dividend provide some buffer, but operating margins remain thin at ~5% and active accounts have slipped.

Implication

The Q3 FY2026 results materially weaken the thesis that LifeVantage had turned a corner with MindBody GLP-1. The 25% revenue decline and 58% EPS drop indicate that the GLP-1 boost may be temporary or facing competitive/regulatory headwinds. While the balance sheet is clean (net cash, no debt), the core business is shrinking. Investors should not rely on past improvement as a base case. Key watch items: (1) whether MindBody GLP-1 revenue can stabilize or grow, (2) active account trends, (3) any regulatory developments around GLP-1 claims. Without a clear catalyst, the risk/reward is skewed to the downside; a margin of safety no longer exists at current ~8x P/E on declining earnings.

Thesis delta

The previous thesis that LifeVantage was an improving, FCF-positive special situation with upside from GLP-1 is now invalidated. The growth inflection has reversed sharply, making the company a high-risk micro-cap with deteriorating fundamentals. The 'wait' stance should become more bearish; evidence now points to a potential 'sell' if the downward trend continues in Q4.